Oncology

2019 ASH Pulse Survey

This 8-question Pulse survey of 55 hematologic oncologists practicing throughout the United States and Europe asks respondents their thoughts on several topics presented at the 2019 American Society of Hematology (ASH) Annual Meeting. Survey questions and additional resources are listed further below.

January 10, 2020

Type 1 Diabetes KOL Interview – UK

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes.

January 8, 2020

Type 1 Diabetes KOL Interview – US, Midwest

This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.

January 8, 2020

Triple-Negative Breast Cancer KOL Interview – UK

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 31, 2019

2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

$4,750.00

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for…

October 18, 2019

2018 Biomedtracker Datamonitor Healthcare Post-ASH Report

The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018.

January 3, 2019

2018 ASH Pulse Survey

This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.

January 2, 2019

Molecular In Vitro Diagnostic and Screening Tests for Oncology

$4,750.00

The market for molecular in vitro diagnostic and screening tests for oncology totaled approximately $1.0bn in 2017, and is projected to expand at a compound annual growth rate (CAGR) of 13.1% during 2017-22, reaching an estimated $1.9bn.

September 13, 2018

PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

$7,500.00

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
Comprehensive Cancer Network (NCCN) guidelines in 2015,

December 22, 2016

United Kingdom, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union member state of the U.K.

U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening

$3,750.00

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.

France, Disease Incidence and Prevalence

$4,850.00

As the aging population in Europe increases and the average life span lengthens, the incidence and prevalence of many major diseases/disorders are expected to increase accordingly and significantly impact the European healthcare industry.

U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging

$4,750.00

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic oncology-related MRI and NMMI systems arena.

U.S. Cancer Statistics Update 2014

$1,950.00

This new report from Medtech Insight includes statistics for new cancer cases, prevalence, and deaths due to the disease in 2014.